Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.61 |
| ▸ | SUV39H2 | Q9H5I1 | 11/20 | 0.44 |
| ▸ | BTK | Q06187 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13780241 | 1.00 | DPP4 (0.61) | DPP4SUV39H2BTKJAK3KDM4D | |
| SCHEMBL13780243 | 0.85 | DPP4 (0.66) | DPP4 | |
| SCHEMBL14844307 | 0.85 | DPP4 (0.61) | DPP4 | |
| SCHEMBL13778043 | 0.83 | DPP4 (0.45) | DPP4SUV39H2KDM4D | |
| SCHEMBL14413658 | 0.83 | PDE10A (0.47) | SUV39H2BTKJAK3KDM4D | |
| SCHEMBL13780242 | 0.80 | DPP4 (0.90) | DPP4 | |
| SCHEMBL13780276 | 0.79 | DPP4 (0.68) | DPP4 | |
| SCHEMBL14051081 | 0.79 | BTK (0.49) | SUV39H2BTKJAK3 | |
| SCHEMBL4201874 | 0.78 | DPP4 (0.57) | DPP4 | |
| SCHEMBL13780009 | 0.78 | DPP4 (0.57) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090182140-A1 | Alicyclic Heterocyclic Compound | CCR4, CCR1, HRH4 | DPP4 641/4885SUV39H2 489/4885BTK 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.